Recent patient data surrounding this compound, specifically the high-dose formulation ZPHC ZPHC, indicate a considerable impact on physique reduction and linked metabolic conditions . Scientists anticipate that this innovative agonist , targeting both GLP-1 and GIP receptors , could provide a substantial improvement in the approach of excess weight